Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -63.89% | 12.12% | -26.76% | -19.71% | 7.23% |
| Total Depreciation and Amortization | -100.00% | 50.00% | -100.00% | -50.00% | 500.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,906.98% | -70.97% | 70.23% | 496.89% | -101.98% |
| Change in Net Operating Assets | -1.38% | 149.38% | 370.34% | -703.88% | -193.14% |
| Cash from Operations | -39.23% | -27.42% | -13.21% | -33.42% | -181.54% |
| Capital Expenditure | -- | -- | 0.00% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 71.39% | -218.15% | 325.45% | -- | 30.59% |
| Cash from Investing | 71.39% | -218.17% | 325.94% | -- | 30.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.52% | 311.76% | 11,500.00% | -- | 1,034.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 316.63% |
| Cash from Financing | -99.61% | 311.76% | 11,500.00% | -- | 8,521.62% |
| Foreign Exchange rate Adjustments | 132.33% | -150.82% | 296.75% | 102.59% | 53.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -141.83% | -285.22% | 318.19% | -5.07% | 239.20% |